UBS AG Reiterates GBX 4,550 Price Target for AstraZeneca plc (AZN)

UBS AG set a GBX 4,550 ($60.46) price target on AstraZeneca plc (LON:AZN) in a report released on Monday, October 9th, www.boersen-zeitung.de reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock.

A number of other analysts also recently weighed in on AZN. J P Morgan Chase & Co set a GBX 4,200 ($55.81) target price on AstraZeneca plc and gave the company a neutral rating in a research report on Wednesday, August 9th. Barclays PLC restated an overweight rating and set a GBX 5,500 ($73.08) price objective on shares of AstraZeneca plc in a research report on Monday, August 7th. Jefferies Group LLC dropped their price objective on AstraZeneca plc from GBX 4,900 ($65.11) to GBX 4,400 ($58.46) and set a hold rating for the company in a research report on Tuesday, August 1st. Investec upgraded AstraZeneca plc from a hold rating to a buy rating and dropped their price objective for the stock from GBX 5,000 ($66.44) to GBX 4,900 ($65.11) in a research report on Wednesday, August 9th. Finally, Shore Capital restated a hold rating on shares of AstraZeneca plc in a research report on Monday, October 9th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of GBX 5,172.64 ($68.73).

AstraZeneca plc (LON AZN) opened at 5181.00 on Monday. The company has a 50-day moving average price of GBX 4,859.28 and a 200 day moving average price of GBX 4,907.26. The company’s market capitalization is GBX 65.59 billion. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00.

TRADEMARK VIOLATION NOTICE: This piece was posted by BBNS and is owned by of BBNS. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://baseballnewssource.com/markets/astrazeneca-plc-azn-given-a-gbx-4550-price-target-by-ubs-ag-analysts-3/1701168.html.

In other news, insider Nazneen Rahman bought 39 shares of the firm’s stock in a transaction on Thursday, July 27th. The stock was acquired at an average cost of GBX 4,370 ($58.07) per share, with a total value of £1,704.30 ($2,264.55).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with our FREE daily email newsletter.

 


Latest News

Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation


Leave a Reply

 
© 2006-2017 BBNS.